the rationale and trial design of the nadim ii trial
Published 2 years ago • 170 plays • Length 0:48Download video MP4
Download video MP3
Similar videos
-
9:33
podcast 300: nadim ii trial offers “quite exciting” results in lung cancer
-
9:17
cancer news: overview of keynote-671 & nadim ii trials by dr. lei deng
-
1:27
pre-treatment ctdna levels significantly predicts os and pfs in nadim ii
-
4:00
designing clinical trials for precision oncology
-
1:36
nadina trial: neoadjuvant ipilimumab nivolumab vs. adjuvant nivolumab in stage iii melanoma
-
19:42
innovating clinical trials: real-world clinical trial design and execution in oncology
-
2:28
clinical trials of neoadjuvant targeted therapy in resectable nsclc
-
1:21
nadim: baseline ctdna as a prognostic factor for pfs
-
3:16
perioperative therapies in nsclc
-
2:58
nadina: promising neoadjuvant immunotherapy strategies for melanoma
-
3:44
immunotherapy as combination and neoadjuvant therapies in nsclc
-
25:30
innovative and emerging trials in ovarian cancer
-
8:09
hemodialysis related trials summary- hemo, ideal and fhn trials
-
2:01
upcoming nsclc trials in 2022: checkmate 816 & keynote-091
-
1:30
advanced orthotopic tumor models for cancer studies
-
6:45
neoadjuvant nivolumab chemotherapy in resectable nsclc | dr. pradip kumar mondal | crsf 2023
-
0:58
adherence & outcomes of neoadjuvant immunotherapy in resectable nsclc
-
2:11
design of the nova trial for ovarian cancer
-
2:12
tumor bulk-rna seq identifies patients at high-risk of progression from nadim trial